Inscrição na biblioteca: Guest
Critical Reviews™ in Therapeutic Drug Carrier Systems

Publicou 6 edições por ano

ISSN Imprimir: 0743-4863

ISSN On-line: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Polymeric Immunonanoparticles Mediated Cancer Therapy: Versatile Nanocarriers for Cell-Specific Cargo Delivery

Volume 35, Edição 1, 2018, pp. 1-64
DOI: 10.1615/CritRevTherDrugCarrierSyst.2017018714
Get accessGet access

RESUMO

The major drawback with conventional therapeutic approaches for cancer therapy is decreased efficacy and redundant therapy associated toxicity and side effects causing increased patient discomfort. With the aim of minimizing these limitations, a vast amount of attention has been given to targeted nanocarrier–based drug delivery systems that possess a several-fold advantage over conventional therapy. Increased research in targeted nanoparticulate systems has led to the development of immunonanoparticles with enhanced efficacy and targeting efficiency along with decreased drug-resistant cancer- and dose-related toxicity. These immunonanoparticle- based therapies, which can be extended to immunotherapy, have gained wide attention, but few formulations will be approved by regulatory agencies in the near future. This review details the various immunonanoparticle systems explored in cancer therapy, with particular emphasis on polymeric nanoparticles. This review describes the mechanisms of immunotherapy and the pathways for targeting dendritic cells for immunotherapy. It also focuses on present status of clinical trials of immunonanoparticles and related patents, as well as various FDA-approved monoclonal antibodies (mAbs) for immunotherapy. Toxicity issues related to immunonanoparticles along with regulatory guidelines for these therapeutic nanoparticles are also discussed.

CITADO POR
  1. Dhas Namdev, Parekh Khushali, Pandey Abhijeet, Kudarha Ritu, Mutalik Srinivas, Mehta Tejal, Two dimensional carbon based nanocomposites as multimodal therapeutic and diagnostic platform: A biomedical and toxicological perspective, Journal of Controlled Release, 308, 2019. Crossref

  2. Su Tianqi, Yang Bo, Gao Tianren, Liu Tongjun, Li Jiannan, Polymer nanoparticle-assisted chemotherapy of pancreatic cancer, Therapeutic Advances in Medical Oncology, 12, 2020. Crossref

  3. Pandey Abhijeet, Dhas Namdev, Deshmukh Prashant, Caro Carlos, Patil Pravin, Luisa García-Martín Maria, Padya Bharath, Nikam Ajinkya, Mehta Tejal, Mutalik Srinivas, Heterogeneous surface architectured metal-organic frameworks for cancer therapy, imaging, and biosensing: A state-of-the-art review, Coordination Chemistry Reviews, 409, 2020. Crossref

  4. Bhargava Arpit, Mishra Dinesh Kumar, Tiwari Rajnarayan, Lohiya Nirmal Kumar, Goryacheva Irina Yu, Mishra Pradyumna Kumar, Immune cell engineering: opportunities in lung cancer therapeutics, Drug Delivery and Translational Research, 10, 5, 2020. Crossref

  5. Dhas Namdev, Mehta Tejal, Sharma Shilpa, Garkal Atul, Yadav Dattatray, Hariharan Kartik, Shamjetshabam Babeeta, Khot Shubham, Kudarha Ritu, Bangar Priyanka, Arbade Gajanan, Kalyankar Pratap, Intranasal gene therapy for the treatment of neurological disorders, in Direct Nose-to-Brain Drug Delivery, 2021. Crossref

  6. Verma Amit, Tiwari Ankita, Saraf Shivani, Panda Pritish Kumar, Jain Ankit, Jain Sanjay K., Emerging potential of niosomes in ocular delivery, Expert Opinion on Drug Delivery, 18, 1, 2021. Crossref

  7. Dhas Namdev, Yadav Dattatray, Singh Ashutosh, Garkal Atul, Kudarha Ritu, Bangar Priyanka, Savjani Jignasa, Pardeshi Chandrakantsing V., Garg Neha, Mehta Tejal, Direct transport theory: From the nose to the brain, in Direct Nose-to-Brain Drug Delivery, 2021. Crossref

  8. Dhas Namdev, Kudarha Ritu, Pandey Abhijeet, Nikam Ajinkya N., Sharma Shilpa, Singh Ashutosh, Garkal Atul, Hariharan Kartik, Singh Amanpreet, Bangar Priyanka, Yadhav Dattatray, Parikh Dhaivat, Sawant Krutika, Mutalik Srinivas, Garg Neha, Mehta Tejal, Stimuli responsive and receptor targeted iron oxide based nanoplatforms for multimodal therapy and imaging of cancer: Conjugation chemistry and alternative therapeutic strategies, Journal of Controlled Release, 333, 2021. Crossref

  9. Moradi Rahman, Mohammadzadeh Reza, Akbari Ali, Kappa-Carrageenan Crosslinked Magnetic Folic Acid-Conjugated Chitosan Nanocomposites for Arginase Encapsulation, Delivery and Cancer Therapy, Nano LIFE, 11, 03, 2021. Crossref

  10. Viswanath Dixita Ishani, Liu Hsuan-Chen, Huston David P., Chua Corrine Ying Xuan, Grattoni Alessandro, Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines, Biomaterials, 280, 2022. Crossref

Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain